title: Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
abstract: OBJECTIVE
  To assess the efficacy of highly active antiretroviral treatment (HAART) on AIDS-Kaposi's sarcoma (KS).
  
  
  METHODS
  Prospective cohort of patients followed for 24 months.
  
  
  METHODS
  Four referral hospitals of the West Paris metropolitan area.
  
  
  METHODS
  Thirty-nine AIDS-KS patients, 42 +/- 9 years old, who began HAART (HIV-protease inhibitor and two nucleoside analogues) between March and December 1996, were enrolled. One was lost to follow-up at month 12.
  
  
  METHODS
  KS response, using criteria of the AIDS clinical trials group (ACTG), CD4 cell counts, and plasma HIV-RNA, assessed every 6 months. ACTG TIS staging of KS.
  
  
  RESULTS
  Eighteen patients had T1 KS and 21 T0 KS. One patient died from KS at month 6. KS improved progressively, with complete and partial response rates of 46% and 28% at month 24, respectively. Only six patients were still receiving systemic KS therapy at month 24. Complete response was observed in 10 of the 19 patients without systemic KS therapy at inclusion. Patients with complete response at month 24 had higher CD4 cell counts than others (465 +/- 343 versus 185 +/- 167 x 10(6)/l; P < 0.01), but the proportion of patients with HIV-1 RNA < 500 copies/ml was not significantly different. An increase in CD4 cell counts from inclusion to month 12 of > 150 x 10(6)/l [odds ratio (OR), 13.4; 95% confidence interval (CI), 2-82] and T0 KS at inclusion: [OR, 7; 95% CI, 1.1-42] were predictive of complete response at month 24.
  
  
  CONCLUSIONS
  HAART appears to have prolonged efficacy on AIDS-KS, even without specific KS therapy, and this effect appears to be linked to the restoration of immune function.
authors.affiliation: Service de médecine interne, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Université Paris V, Boulogne, France.
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: E
authors.initials: E
authors.lastname: Vasseur
authors.forename: A
authors.initials: A
authors.lastname: Beauchet
authors.forename: P
authors.initials: P
authors.lastname: Aegerter
authors.forename: H
authors.initials: H
authors.lastname: Berthé
authors.forename: P
authors.initials: P
authors.lastname: de Truchis
authors.forename: D
authors.initials: D
authors.lastname: Zucman
authors.forename: E
authors.initials: E
authors.lastname: Rouveix
authors.forename: P
authors.initials: P
authors.lastname: Saiag
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors